# SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma

> **NCT01482442** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 496 (actual)

## Conditions studied

- Liver Carcinoma

## Interventions

- **DRUG:** sorafenib
- **DRUG:** SIR-Sphere

## Key facts

- **NCT ID:** NCT01482442
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 496 (ACTUAL)
- **Last updated:** 2017-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482442, "SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01482442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*